Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Jpn J Clin Oncol
; 53(10): 912-921, 2023 Oct 04.
Article
in En
| MEDLINE
| ID: mdl-37486002
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Non-Hodgkin
/
Lymphoma, Follicular
/
Antineoplastic Agents
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Jpn J Clin Oncol
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: